Arrowhead Pharmaceuticals Files IND For Phase 1b Study Of ARO-HIF2 For Treatment Of Clear Cell Renal Cell Carcinoma

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1b adaptive dose-finding

Benzinga · 12/11/2019 12:30

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1b adaptive dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).